Polymorphisms in GSTM1, GSTT1 and GSTP1 genes in humans are associated with the reduction of enzymatic activity toward several substrates, including those in tobacco smoke. To investigate the potential role these polymorphisms have, as modulators of early-onset lung cancer risk, a population-based case-control study involving earlyonset lung cancer cases was performed. Biological samples were available for 350 individuals diagnosed 550 years of age identified from the metropolitan Detroit Surveillance, Epidemiology and End Results (SEER) program and 410 cases of age, race and sex-matched controls ascertained through random digit dialing. African Americans carrying at least one G allele at the GSTP1 locus were 2.9-fold more likely to have lung cancer compared with African Americans without a G allele after adjustment for age, sex, pack years of smoking and history of lung cancer in a first-degree relative (95% CI 1.29--6.20). African Americans with either one or two risk genotypes at the GSTM1 and GSTP1 loci were at increased risk of having lung cancer compared with those having fully functional GSTM1 and GSTP1 genes (OR ¼ 2.8, 95% CI 1.1--7.2 and OR ¼ 4.0, 95% CI 1.3--12.2, respectively). No significant single gene associations between GSTM1, GSTT1 or GSTP1 and early-onset lung cancer were identified in Caucasians, after adjusting for age, sex, pack years and family history of lung cancer. However, our results suggest that specific combinations of glutathione S-transferase polymorphisms increase the risk of early-onset of lung cancer. Joint analysis of these genotypes may identify individuals who are at a higher risk of developing early-onset lung cancer with a greater certainty than single gene studies.
Introduction
Lung cancer is the leading cause for cancer-related deaths in both men and women in USA (1) . The median age of lung cancer diagnosis in USA is 70 years, with 6.7% of cases diagnosed before 50 years of age (2, www.seer.cancer.gov). These early-onset lung cancer cases are more likely to be diagnosed with adenocarcinoma and to have a family history of lung cancer than those diagnosed at later ages (3--6) . However, even in those diagnosed at young ages, tobacco smoking remains the major risk factor associated with lung cancer development (7) . Of the several thousand chemicals found in tobacco smoke, at least 50 are known to be carcinogenic, including polycyclic aromatic hydrocarbons (PAHs), aromatic amines and nitroso compounds (8) . It is hypothesized that individuals diagnosed with lung cancer at an early age are more susceptible to lung carcinogens and this is thought to have a stronger genetic component than in individuals diagnosed late in life.
Susceptibility to tobacco smoke is likely to result from each individual's capacity to activate and detoxify carcinogens. Cytochrome P450 enzymes (i.e. Phase I enzymes) oxidize procarcinogens found in tobacco smoke, resulting in reactive metabolites that damage DNA. Phase II enzymes protect a cell by detoxifying these metabolites into compounds that are readily excreted from the body (9). Glutathione S-transferases (GSTs) are a class of Phase II enzymes that are present in many tissues, including lung (10) . Alpha (a), kappa (k), mu (m), sigma (s), zeta (z), pi (p), theta (u) and omega (v) (11) are the eight major classes of genes known. Polymorphisms in glutathione S-transferase m (GSTM1), glutathione S-transferase u (GSTT1) and glutathione S-transferase p (GSTP1) genes in humans are associated with a lack or a reduction of enzymatic activity toward several substrates, including those found in tobacco smoke (12--15) .
A common deletion polymorphism in the GSTM1 gene on chromosome 1p13.3 renders the enzyme inactive (16) , thereby eliminating this route of conjugation and detoxification of reactive metabolites, particularly epoxide metabolites of PAHs (17) . The GSTT1 gene, located on chromosome 22q11. 23 , has also been found to have a deletion polymorphism that results in an absence of enzyme activity (18) . GSTT1 participates in detoxification of carcinogenic intermediates produced from tobacco smoke, namely monohalomethanes and butadiene. GSTP1 detoxifies PAHs and is the most abundant GST isoform in the lungs (10) . A single nucleotide polymorphism in exon 5 (Ile105Val, 313A ! 313G) of the GSTP1 gene, located on chromosome 11q13, results in significantly lower conjugating activity among individuals who carry one or more copies of the G (guanine) allele (Ile/ Val or Val/ Val) compared with those who have the A/A (adenine/adenine; Ile/ Ile) genotype (19) . Having at least one copy of the G allele in GSTP1 is also associated with increased levels of hydrophobic adducts in the lung and higher levels of PAH--DNA adducts in human lymphocytes (20) . Because of their role in the metabolism of carcinogens in tobacco smoke, these polymorphisms are potential modulators of lung cancer risk.
While risks associated with these polymorphisms have been studied in lung cancer, little attention has been paid to early-onset disease, where genetic susceptibility to lung carcinogens may be particularly important. To investigate the potential role of these GSTs, alone and in combination, as modulators of early-onset lung cancer risk, a populationbased case-control study of early-onset lung cancer was performed.
Materials and methods

Population sample
Eligible early-onset cases were identified through the metropolitan Detroit Cancer Surveillance System (MDCSS), a participant in the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program. Cases were defined as those with a primary neoplasm of the lung or the bronchus, 550 years of age, residing in the Wayne, Macomb and Oakland counties of Michigan at the time of diagnosis. Data collection has taken place continuously since September 15, 1990 . Cases 545 years were oversampled in the early years of the study. Population-based controls were ascertained concurrently through random digit dialing, frequency matched to cases by race, sex, 5-year age group and county of residence. Of the 1213 early-onset cases identified over this 13-year period, interviews were completed for 704 cases (58.0%). Eligible controls (498%) contacted through random digit dialing agreed to participate in the study (n ¼ 797); however, eligibility was difficult to determine because of refusal to complete the screening questionnaire. In a sample of contacts from 2000 to 2002, of the 2748 randomly dialed numbers that were answered by a member of the household, 49.3% were ineligible owing to age, 37.2% refused to answer the questionnaire, 12.4% participated in the study and only 1.1% were eligible but declined to participate in the study.
This protocol was approved by the local institutional review board. Informed consent was obtained from all subjects prior to initiation of the interview and again prior to biospecimen collection. Trained interviewers conducted structured telephone interviews to collect demographic information, health history, cigarette use and family history of lung cancer in a first degree relative.
Biological samples with GST genotyping results were available for 350 interviewed cases and 410 interviewed controls. Owing to the rapidly fatal nature of lung cancer, it was necessary to collect 118 (33.7%) paraffinembedded tumor blocks to obtain DNA from deceased cases. The use of these blocks as the DNA source for genotyping could lead to bias if the tumor tissue from the blocks contained deletions or other mutations not seen in normal tissue obtained from the blocks. When the genotype frequencies by tissue type (normal, tumor or mixed normal and tumor) were examined using Fisher's exact test, there were no differences in genotyping results by tissue type for GSTM1 (P-value ¼ 0.79), GSTT1 (P-value ¼ 0.40) or GSTP1 (P-value ¼ 0.55). Any bias from the use of DNA from tumor blocks is minimal. The remainder of DNA samples in case subjects was extracted from either venous blood (44.6%) or buccal cells (21.7%). All DNA from control subjects were collected through blood (67.1%) or buccal cells (32.9%).
Genotyping DNA was isolated from whole blood with the Genomic DNA Purification System (Gentra Systems, Minneapolis, MN), from buccal swabs with the BuccalAmp TM DNA Extraction Kit (Epicentre Technologies, Madison, WI) or from paraffin-embedded tissue with the QIAamp DNA Mini Kit (Qiagen, Valencia, CA) following the manufacturers' protocols. When multiple biospecimens were obtained from a study participant, DNA extracted from blood was used preferentially, followed by those from buccal swabs and then from normal tissue within paraffin blocks.
DNA isolated from buccal cells or paraffin embedded tissue was preamplified using a nested PCR strategy. Preamplification (outer amplification) was carried out in a 25 ml reaction mixture containing 2.5 mmol/l MgCl 2 , 0.5 mmol/l of the gene specific-primers (Table I) G polymorphism of GSTP1 and null mutations of GSTM1 and GSTT1 were determined by using the TaqMan 5 0 -nuclease assay. HBB (b-globin) served as a positive control in all reactions. Gene specific allelic discrimination (described below) was determined directly from amplification of DNA from whole blood and used preamplified DNA from buccal or paraffin-embedded tissue. Five percent of the products were randomly sequenced and 10% of genotypes were carried out in duplicate and a concordance of 100% was achieved. Table I lists the sequences of the primers and the probes used in genotyping the GSTM1, GSTT1 and GSTP1 polymorphisms.
The GSTM1 null mutation was assayed using quantitative PCR methods described earlier (21) . Briefly, 25 ng of DNA extracted from whole blood or 2 ml of preamplification reaction mixture was mixed with forward (GSTM1-194F) and reverse (GSTM1-273R-2) primer and the product was detected with a fluorescent probe (GSTM1-215T) at an annealing temperature of 55 C. The GSTT1 null mutation was determined as previously described (22) . Briefly, following amplification with annealing temperature at 58 C, the PCR products were electrophoresed through 3% NuSieve 3:1 agarose (FMC) and visualized with ethidium bromide.
Primers for amplification of the region of the GSTP1 gene containing the functional polymorphism and fluorescent probes for allelic discrimination, were designed using Primer Express software (Applied Biosystems). Standard TaqMan conditions were applied in an ABI PRISM 7900 Sequence Detection System (Applied Biosystems) for amplification and detection of both alleles. Briefly, 25 ng of DNA derived from whole blood or 2 ml of preamplification reaction mixture, was added to 1x Universal PCR mix (Applied Biosystems) containing forward (GSTP1-IF) and reverse (GSTP1-IR) primers and GSTP1 A 313 allele (GSTP1-A) and GSTP1 G 313 allele (GSTP1-G) probes at an annealing temperature of 64 C. For GSTM1 genotyping, there were four amplification failures among the controls and five among the cases. GSTT1, had 12 amplification failures among the controls and 19 among the cases. For GSTP1, there were three amplification failures among the controls and six among the cases. The remaining missing genotypes (25 for GSTM1, 25 for GSTT1 and 27 for GSTP1) were all in case subjects, when there was insufficient sample available to perform genotyping.
Statistical analysis
Distributions of demographic variables were compared between cases and controls using x 2 -tests for categorical variables and t-tests for continuous variables. Unconditional logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CI) to measure the association between lung cancer and genotype. All analyses presented in the Tables (II--V) were stratified by race. Potential confounders, including sex, age at diagnosis or interview (continuous), family history of lung cancer in a first degree relative (dichotomous) and pack years of cigarette smoking (continuous) were included in the final models. Subjects were categorized as ever smokers if they reported smoking at least 100 cigarettes in their lifetime. Pack years were calculated using the reported number of cigarettes smoked per day and the number of years smoked. Light smokers were those who Table I . Primer and probe sequences used in GSTM1, GSTT1 and GSTP1 genotyping
smoked less than or equal to the mean number of pack years among smoking controls in each racial group ( 18 pack years of smoking in Caucasians, 14 in African Americans); heavy smokers were those who smoked more than the mean number of pack years (!19 pack years of smoking in Caucasians, !15 in African Americans). GSTM1 null homozygotes, GSTT1 null homozygotes and GSTP1 A/G and G/G genotypes were considered to be risk genotypes for lung cancer development in this analysis. To evaluate the risk associated with combinations of genotypes, individuals were categorized as having 0, 1, 2 or 3 of the risk genotypes, with those in the 0 category used as the reference group. Our genotyping methods did not distinguish between individuals homozygous, non-null and heterozygous for GSTM1 and GSTT1, therefore, Hardy--Weinberg equilibrium tests of genotype distribution in controls, by race, were conducted only for GSTP1. Potential effect modifiers were evaluated by the addition of interaction terms in the logistic model and tested for significance using the P-value (two sided) of the likelihood ratio test (LRT) that compared models with and without the interaction term. Gene--gene interactions were also examined using this method. All analyses were performed using SAS 8.02 (23) .
Results
Participant characteristics are presented in Table II . African Americans comprised 29% of the cases and the controls. Mean ages of the cases and the controls were 42.1 and 41.1, respectively. The majority of cases reported ever smoking (89.7%), while controls were less likely to report ever smoking (54.9%). A total of 15% of Caucasian cases and 20% of African American cases reported having at least one first degree relative with lung cancer; only 9.5% of controls of either race reported such a family history (x 2 P-value ¼ 0.08 for Caucasians, x 2 P-value ¼ 0.02 for African Americans). Adenocarcinoma was the most common cell type diagnosed in this young-onset population (47.7%), followed by small cell carcinoma, squamous cell carcinoma, and large cell carcinoma (13.2, 11.7 and 9.4%, respectively). (Table IV) . Interactions between genotype and smoking exposure were also examined. In Caucasians, the interactions between pack years and GSTM1 (P ¼ 0.02) and pack years, and GSTT1 (P ¼ 0.02) were statistically significant, although no significant interaction between pack years and GSTP1 (P ¼ 0.76) was identified.
The effects of combinations of risk genotypes on early-onset lung cancer risk were also examined. Caucasian heavy (Table IV) . Risk was also high for Caucasian heavy smokers who carried the GSTT1 null and GSTP1 risk genotypes compared with their counterparts with fully functional GSTT1 and GSTP1 genes (OR ¼ 4.6 95% CI 1.0--22.1), although statistical significance was not attained. Table V smoking and GSTM1 (P ¼ 0.15), GSTT1 (P ¼ 0.62) or GSTP1 (P ¼ 0.87) were identified. The effects of the combinations of risk genotypes on earlyonset lung cancer risk were also examined in African Americans. A statistically significant interaction between the GSTM1 and GSTT1 genotypes was observed (LRT x 2 ¼ 4.8, P-value ¼ 0.03) (data not shown) with risk increased for carriers of both risk genotypes relative to a decreased risk in carriers of only one risk genotype. African Americans with either GSTT1 null or GSTP1 risk genotypes were 3.8-fold more likely to have lung cancer compared with African Americans with fully functioning GSTT1 and GSTP1 genes (95% CI 1.4--9.9). African Americans with either one or two risk genotypes at the GSTM1 and GSTP1 loci were at higher risk of having lung cancer compared with those with fully functional GSTM1 and GSTP1 genes (one risk genotype OR ¼ 2.8, 95% CI 1.1--7.2 and two risk genotypes OR ¼ 4.0, 95% CI 1.3--12.2; P-value trend for ¼ 0.02). Stratification by smoking history in African Americans did not reveal any statistically significant differences between amount smoked and genotype, although the P-values for trend were close to significance in the light smoking category.
For all subjects combined, risk of early-onset lung cancer increased as the number of GST risk genotypes an individual carried increased (one risk genotype OR ¼ 1.4, 95% CI 0.8--2.4, two risk genotypes OR ¼ 1.7, 95 % CI 1.0--3.1 and 3 risk genotypes OR ¼ 2.3 95% CI 1.0--5.4, P-value for trend ¼ 0.03) after adjustment for age, race, sex, pack years of smoking and family history of lung cancer (data not shown). A significant trend for increasing risk with increasing number of GST risk genotypes was also seen in heavy smoking Caucasians (P-value for trend ¼ 0.03).
Discussion
Few studies have focused on genetic polymorphisms associated with risk of early-onset lung cancer. To our knowledge, this study is the largest on early-onset lung cancer in the current literature. Other published papers of early-onset lung cancer include a pooled analysis of Caucasians 545 years (25) and a subset of cases 555 years from a large hospital-based study of Caucasians (26) . An early-onset population is particularly appropriate for studies of genetic susceptibility, but lung cancer 560 years is rare, making such studies difficult. Given the number of carcinogen-metabolizing enzymes now known and the complex pathways in which they are thought to interact, examining combinations of these genotypes may provide better insight to the mechanisms involved in lung carcinogenesis. The results presented provide evidence that certain GST genotypes, particularly in combination, are associated with risk of early-onset lung cancer.
Single gene effects
No statistically significant association was observed between GSTM1 null genotype and lung cancer in Caucasians or African Americans regardless of level of smoking in our early-onset population, with ORs of 1.3 and 1.5 in Caucasians and African Americans, respectively. A pooled analysis of Caucasian early-onset (age 545 years) lung cancer cases reported similar findings (25) . These findings are also consistent with two meta-analyses that reported moderately (520%) increased risk of lung cancer associated with the GSTM1 null genotype (27, 28) . The majority of the studies included in the meta-analyses, individually, did not find statistically significant increases in risk associated with GSTM1 genotype and lung cancer; however, taken together, significance was attained. Similar to the odds ratio reported here for African Americans (OR ¼ 1.5), Ford et al. reported a 2.1-fold increase in the risk of lung cancer in African Americans associated with a GSTM1 null genotype after adjusting for age, sex and smoking (95% CI 1.1--4.1) (29) . Given the current literature, GSTM1 genotype is a likely risk factor for lung cancer, albeit one with a small magnitude of effect. Risk may be most evident in certain ethnic populations, histological types or when analyzed in gene--gene and gene--environment interactions (30--33) . Heavy smoking Caucasians in our study population were found to be at a higher risk of early-onset lung cancer if they carried a null GSTT1 genotype. Hou et al. (34) reported a gene--environment interaction for increased risk of lung cancer associated with GSTT1 null genotype in a small number of heavy smokers (423 pack years) compared with light smokers with GSTT1 null genotypes (OR ¼ 9.3 95% CI 1.9--46.3). Another study of 144 Caucasian early-onset cases (545 years) found borderline increased risk, after adjusting for age, sex and study number (OR ¼ 1.2, 95% CI 1.0--1.6) (25) . Two other publications to date reported statistically significant increased risk of lung cancer associated with GSTT1 null genotype in Caucasians (35, 36) . Several other studies report no association between GSTT1 genotype and lung cancer risk (37--44) .
This study is the first to report increased risk of early-onset lung cancer in African Americans who carried the A/G or G/G genotypes at the GSTP1 locus. Of the GST genotypes explored in this analysis, GSTP1 polymorphisms are the least represented in the lung cancer literature. A pooled analysis of studies examining GSTP1 genotypes suggested increased risk of lung cancer associated with the G/G genotype (OR ¼ 2.0, 95% CI 1.0--4.1, adjusted for age, hospital and tobacco smoking, A/A and A/G genotypes comprised the reference group) (41) . However, the vast majority of subjects in these studies have been Caucasians without age of onset limitations and did not independently report statistically significant associations (45--49) . Investigating the relationships between smoking, GSTP1 genotype and lung cancer, Miller et al. (50) reported an interaction between GSTP1 G/G genotype and cumulative smoking exposure, with greater risks for current smokers than for exsmokers. In our study, risk associated with GSTP1 genotype in African Americans did not appear to be modified by smoking level. However, in our young-onset population, very few cases could be classified as exsmokers and the range of pack years reported among smokers was narrow.
GST combinations and their effects
There are limitations inherent in the single gene approach taken in most lung cancer association studies. The majority of cancers are regarded as complex diseases, which follow a polygenic model of inheritance. By examining risk associated with genotype combinations, our study acknowledges the complexity of the underlying mechanisms of lung cancer development and attempts to move data analysis in a direction better suited to identify the contributions of multiple genes.
Increased risk of lung cancer associated with GSTM1 null and GSTT1 null genotype combinations was identified in our population of Caucasian heavy smokers. Similar findings have been reported in Finnish squamous cell lung carcinoma cases (n ¼ 44) who had 440 pack years of smoking (OR ¼ 3.0, 95% CI 1.1--8.4) (45). Kelsey et al. (44) reported a 2.9-fold increase in risk in African Americans and Mexican Americans with this genotype combination after adjusting for smoking, age, sex and ethnicity (95% CI 1.1--7.7). Conversely, other studies did not observe this association (37, 41, 51, 52) . We did not find increased risk of early-onset lung cancer in those who jointly carry both GSTT1 and GSTP1 risk genotypes. This agrees with findings from several other populations, including Asian populations (38, 52) and several European studies (39, 41, 45, 47, 48) . This paper reports the novel finding of an increased risk of lung cancer in African Americans who carry one or two risk GSTM1 and GSTP1 genes. Other epidemiological studies have also supported the relationship between increased risk of lung cancer and this genotype combination (52--54) . In particular, a study of younger age-at-onset individuals ( 55 years) found a 4-fold increase in risk of lung cancer in those who jointly carried the GSTP1 G/G genotype and GSTM1 null genotype after adjustment (OR ¼ 4.03, 95% CI 1.47--11.08) (25) . However, other studies not limited to early-onset cases have not corroborated these findings (38--40,45,48) .
A dose--response relationship was observed between the number of risk genotypes an individual carries and risk of early-onset lung cancer. The vast majority of research has focused on the joint effects of two genotype combinations, interactions with specific histology types or noted that stratified sample size limits sufficient statistical power (39--42,45,55) . While the functional role of GSTs in the carcinogen metabolism pathway has been established, the relative importance and combined functioning in conjunction with one another is yet to be determined. In this analysis of joint effects an assumption was made that each genotype confers a similar degree of risk.
Limitations found in most studies in lung cancer patients hold true in this study. The rapidly fatal nature of lung cancer makes obtaining biospecimens difficult and reduces the size of the population available for molecular epidemiology studies. During the first 4 years of subject accrual, DNA was not collected at the time of the interview. When a biospecimen was requested several years later, only 52 of 126 cases (50.1%) had archived tissue available and only 52 of 126 (41.3%) of controls were able to provide a sample. When DNA was requested at the time of the interview, 55.3% of controls agreed to give a sample and 51.1% of cases gave a blood or buccal sample or had archived tissue available. Those who did participate have genotype and allele frequencies comparable to published work (56, 57) . Additionally, there were no differences in smoking, age or family history of lung cancer between cases who did or did not provide a biospecimen (P ¼ 0.84, 0.43 and 0.85, respectively). Among controls, those providing a biospecimen were slightly older (mean age ¼ 41.1 versus 39.2, P 5 0.0001) than those who did not, but there were no statistically significant differences in smoking (P ¼ 0.11) or family history (P ¼ 0.10).
Given the difficulty in collecting biospecimens, coupled with the relatively low frequency of certain polymorphisms, some ORs are based on small sample sizes. Thus, the results presented may not provide an accurate estimate of the true ORs. Sample size limits the ability to study gene--environment interactions. Unknown or known but unmeasured confounders and effect modifiers (e.g. chemical, hormonal or dietary factors), may be partially responsible for some of the associations identified.
Detailed information for smoking, the overwhelming risk factor for lung cancer, was collected from all participants and the use of pack years, a continuous variable, results in less residual confounding than categorizing smoking into a two level, ever/never variable (58) . Additionally, smokers were stratified into light and heavy categories by race, to account for the differences in smoking patterns seen between Caucasians and African Americans. Lower levels of cumulative amount smoked (i.e. pack years) reported by African Americans compared with Caucasians are consistent with previous local and national reports on tobacco use (59, 60) . The possible excess in risk in African American light smokers and Caucasian heavy smokers is likely to reflect the greater sample sizes and therefore power in these strata. However, the data may also suggest susceptibility to lung cancer differs by levels of exposure to tobacco smoke. The greater effect of metabolic polymorphisms at lower levels of tobacco exposure have been identified in lung cancer, particularly for cytochrome P-450 1A1 (CYP1A1) polymorphisms (61, 62) . The evidence suggesting a differential risk associated with GST genotypes, amount of tobacco exposure and lung cancer risk is not clear, with some studies supporting greater effects at lower levels of exposure (63, 64) , and others finding the opposite (65, 66) . In our population, significant interactions between pack years of smoking and GSTM1 and pack years of smoking and GSTT1 were identified in Caucasians. These findings may lend support to the theory that susceptibility to lung cancer is moderated by both tobacco exposure and genotype.
Our study had several important strengths. Cases and controls were both population-based and included a sufficient number of African Americans to estimate risk of lung cancer in this under-studied population. The focus on early-onset disease and the African American population, where genetic susceptibility might be greater, is unique in the current GST literature (33, 67) . Stratifying analyses by race decreased the possibility of population stratification biasing the results. Our ability to examine and adjust for known confounders, collected through structured interviews, is an additional strength of this study. In addition, incident cases were identified quickly after diagnosis, which limits survival bias. This may prove to be especially important if these GSTs play a role in response to treatment and subsequent survival.
This study focused on cases diagnosed before 50 years of age, well below the median age of onset for lung cancer (70 years for Caucasians and 66 years for African Americans) (68) . Although 'early-onset' is arbitrarily defined, younger age of onset is suggestive of increased genetic susceptibility to lung cancer. Familial aggregation of disease has been more strongly identified in younger age groups, suggesting a heritable component to lung cancer (69--72) . More recently, linkage to a region on chromosome 6 has been described in familial lung cancer adding evidence for the role of genetic susceptibility for this disease, particularly when age of onset is young (73) .
Our results suggest that specific combinations of GSTM1, GSTT1 and GSTP1 are involved in lung cancer susceptibility in early-onset cases. However, larger sample sizes are needed to confirm these findings and clarify differences associated with other modifiers of early age of onset lung cancer risk. Joint analysis of genes involved in carcinogen metabolism pathways may identify individuals who are at higher risk of developing lung cancer with a greater certainty than single gene studies.
